UY32353A - Compuestos de soluciones oculares tópicas para suministrar concentraciones efectivas del agente activo al segmento posterior del ojo - Google Patents

Compuestos de soluciones oculares tópicas para suministrar concentraciones efectivas del agente activo al segmento posterior del ojo

Info

Publication number
UY32353A
UY32353A UY0001032353A UY32353A UY32353A UY 32353 A UY32353 A UY 32353A UY 0001032353 A UY0001032353 A UY 0001032353A UY 32353 A UY32353 A UY 32353A UY 32353 A UY32353 A UY 32353A
Authority
UY
Uruguay
Prior art keywords
active agent
effective concentrations
eye segment
back eye
supply effective
Prior art date
Application number
UY0001032353A
Other languages
English (en)
Inventor
Masood A Chowhan
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of UY32353A publication Critical patent/UY32353A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compuestos farmacéuticos que contienen tandospirona para la administración ocular tópica. Los compuestos son útiles para suministrar tandospirona al segmento posterior del ojo, a efecto de tratar desordenes que afectan dichos tejidos.
UY0001032353A 2008-12-22 2009-12-21 Compuestos de soluciones oculares tópicas para suministrar concentraciones efectivas del agente activo al segmento posterior del ojo UY32353A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13970108P 2008-12-22 2008-12-22

Publications (1)

Publication Number Publication Date
UY32353A true UY32353A (es) 2010-04-30

Family

ID=41559537

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032353A UY32353A (es) 2008-12-22 2009-12-21 Compuestos de soluciones oculares tópicas para suministrar concentraciones efectivas del agente activo al segmento posterior del ojo

Country Status (15)

Country Link
US (1) US20100160342A1 (es)
EP (1) EP2367528A1 (es)
JP (1) JP2012513393A (es)
KR (1) KR20110099044A (es)
CN (1) CN102264344A (es)
AR (1) AR074828A1 (es)
AU (1) AU2009330517A1 (es)
BR (1) BRPI0923502A2 (es)
CA (1) CA2747917A1 (es)
CL (1) CL2009002197A1 (es)
MX (1) MX2011005586A (es)
RU (1) RU2011130552A (es)
TW (1) TW201028176A (es)
UY (1) UY32353A (es)
WO (1) WO2010074961A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103664905B (zh) * 2013-12-25 2015-10-14 四川科瑞德制药有限公司 盐酸坦度螺酮晶型ii及其制备方法
CN108619100B (zh) * 2017-03-16 2022-05-13 四川科瑞德制药股份有限公司 一种氮杂螺酮类药物注射剂及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US5648348A (en) * 1991-10-28 1997-07-15 Mona Industries, Inc. Phospholipid antimicrobial compositions
US5286719A (en) * 1991-10-28 1994-02-15 Mona Industries, Inc. Phospholipid virucidal compositions
CA2166722A1 (en) * 1994-05-06 1995-11-16 Manoj L. Maniar Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
PT877600E (pt) * 1996-08-09 2004-02-27 Alcon Mfg Ltd Sistemas conservantes para composicoes farmaceuticas contendo ciclodextrinas
US6120758A (en) * 1998-07-16 2000-09-19 Shaklee Corporation Preservative system for topically applied products
US20030207890A1 (en) * 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
MX2009000885A (es) * 2006-07-25 2009-02-05 Osmotica Corp Soluciones oftalmicas.
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
TW200904485A (en) * 2007-05-18 2009-02-01 Alcon Res Ltd Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions
AU2009223649B2 (en) * 2008-03-11 2013-08-29 Novartis Ag Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength

Also Published As

Publication number Publication date
WO2010074961A1 (en) 2010-07-01
CN102264344A (zh) 2011-11-30
AU2009330517A1 (en) 2010-07-01
TW201028176A (en) 2010-08-01
EP2367528A1 (en) 2011-09-28
JP2012513393A (ja) 2012-06-14
RU2011130552A (ru) 2013-01-27
CA2747917A1 (en) 2010-07-01
AR074828A1 (es) 2011-02-16
US20100160342A1 (en) 2010-06-24
BRPI0923502A2 (pt) 2019-09-24
CL2009002197A1 (es) 2011-02-11
KR20110099044A (ko) 2011-09-05
MX2011005586A (es) 2011-06-20

Similar Documents

Publication Publication Date Title
CL2019003433A1 (es) Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de receptor tirosina quinasa (rtk), o un inhibidor de la angiogénesis, y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).
AR120961A2 (es) Método y composición para tratar hipertensión ocular y glaucoma
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112012023021A2 (pt) compostos de indazol e seus usos
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
EA202091999A3 (ru) Применение ингибиторов dpp iv
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
UY31294A1 (es) Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
AR088267A1 (es) Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos
ECSP10010428A (es) Derivados de indazol
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
GT200900296A (es) Composición farmacéutica que comprende la combinación de un agente anti inflamatorio no esteroideo y un agente anticonvulsivante.
CL2009002204A1 (es) Composicion intravenosa biocompatible que comprende un factor de coagulacion incluido en microparticulas de acido alginico o sales del mismo.
UY32353A (es) Compuestos de soluciones oculares tópicas para suministrar concentraciones efectivas del agente activo al segmento posterior del ojo

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20201223